During his postdoctoral fellowship at Yale School of Medicine, Dr. Raval spent years studying a precise and devastating phenomenon: how oxygen deprivation — hypoxia — triggers catastrophic lung damage and hyperinflammation. His lab established the mechanisms, mapped the pathways, and demonstrated solutions in animal models. They could protect mice from hypoxia-driven lung injury.
As the pandemic swept the globe, Dr. Raval watched with a particular and painful clarity. The virus, he understood, was simply a trigger. The real killer was hypoxia-mediated hyperinflammation — the exact biology he and his colleagues at Yale had spent years solving. Academic scientists across the world had already established the mechanisms and identified potential interventions. The knowledge existed. The solutions existed, at least in principle.
But millions died anyway.
Not because the science failed — but because the science never left the laboratory. Translational research, the bridge between discovery and treatment, had been neglected. Novel innovations sat in published papers while patients ran out of time.
“I could save lab mice from hypoxia. I could not save humans during COVID. That gap — between what science knows and what medicine can do — is why CelerisAI exists.”
— Dr. Chintan Raval, Founder & CEO, CelerisAI